Project UpdateApr 30, 2026, 08:07 AM
SGMO to Present Neurology Pipeline & MINT Platform Data at ASGCT Meeting
AI Summary
Sangamo Therapeutics announced the acceptance of three abstracts for presentation at the 29th ASGCT Annual Meeting, held May 11-15, 2026. The presentations will detail advances in the company's neurology pipeline, including zinc finger epigenetic regulation for chronic neuropathic pain and prion disease, and updated data from its protein-guided MINT platform for integrating large DNA sequences into the genome. These advancements demonstrate the potency, versatility, and specificity of their genome engineering platform, potentially expanding treatment possibilities for complex diseases and offering new collaboration opportunities.
Key Highlights
- Three Sangamo abstracts accepted for presentation at the 29th ASGCT Annual Meeting.
- Presentations scheduled for May 11-15, 2026, in Boston, MA.
- Two posters detail zinc finger repressors (ZFRs) for chronic neuropathic pain (Nav1.7 gene) and prion disease (Prion protein expression).
- One platform presentation showcases updated data from the MINT platform for integrating large DNA payloads.
- MINT platform could be deployed internally for neurology and offer new collaboration opportunities.
Price Impact
More from SGMO